Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported fr...
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation...
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechn...
Canaccord Genuity analyst Tania Armstrong-Whitworth initiates coverage on Eupraxia Pharmaceuticals (TSX:EPRX) with a Specula...
At 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- an...
